Skip to main content

Table 2 General guidance for corticosteroid management of immune-related adverse events

From: Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

Grade of immune-related AE (CTCAE/equivalent)

Corticosteroid management

Additional notes

1

• Corticosteroids not usually indicated

• Continue immunotherapy

2

• If indicated, start oral prednisone 0.5-1 mg/kg/day if patient can take oral medication.

• If IV required, start methylprednisolone 0.5-1 mg/kg/day IV

• If no improvement in 2–3 days, increase corticosteroid dose to 2 mg/kg/day

• Once improved to ≤grade 1 AE, start 4–6 week steroid taper

• Hold immunotherapy during corticosteroid use

• Continue immunotherapy once resolved to ≤grade 1 and off corticosteroids

• Start proton pump inhibitor for GI prophylaxis

3

• Start prednisone 1-2 mg/kg/day (or equivalent dose of methylprednisolone)

• If no improvement in 2–3 days, add additional/alternative immune suppressant

• Once improved to ≤ grade 1, start 4–6-week steroid taper

• Provide supportive treatment as needed

• Hold immunotherapy; if symptoms do not improve in 4–6 weeks, discontinue immunotherapy

• Consider intravenous corticosteroids

• Start proton pump inhibitor for GI prophylaxis

• Add PCP prophylaxis if more than 3 weeks of immunosuppression expected (>30 mg prednisone or equivalent/day)

4

• Start prednisone 1-2 mg/kg/day (or equivalent dose of methylprednisolone)

• If no improvement in 2–3 days, add additional/alternative immune suppressant, e.g., infliximab

• Provide supportive care as needed

• Discontinue immunotherapy

• Continue intravenous corticosteroids

• Start proton pump inhibitor for GI prophylaxis

• Add PCP prophylaxis if more than 3 weeks of immunosuppression expected (>30 mg prednisone or equivalent/day)

  1. Note: For steroid-refractory cases and/or when steroid sparing is desirable, management should be coordinated with disease specialists. AE, adverse event